Blue Trust’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$197K Buy
1,392
+157
+13% +$25.2K ﹤0.01% 769
2026
Q2
$208K Buy
1,235
+700
+131% +$104K ﹤0.01% 778
2026
Q1
$70.5K Buy
535
+526
+5,844% +$69.8K ﹤0.01% 1177
2025
Q4
$1.28K Hold
9
– – ﹤0.01% 2239
2025
Q3
$1.26K Hold
9
– – ﹤0.01% 2271
2025
Q2
$1.13K Hold
9
– – ﹤0.01% 2234
2025
Q1
$995 Sell
9
-69
-88% -$8.74K ﹤0.01% 2294
2024
Q4
$10.6K Sell
78
-270
-78% -$33.4K ﹤0.01% 1814
2024
Q3
$47.9K Buy
348
+220
+172% +$30.2K ﹤0.01% 1584
2024
Q2
$17.7K Buy
128
+79
+161% +$10.8K ﹤0.01% 1716
2024
Q1
$6.76K Buy
49
+5
+11% +$683 ﹤0.01% 1558
2023
Q4
$5K Buy
44
+28
+175% +$3.22K ﹤0.01% 1851
2023
Q3
$2K Buy
+16
New +$1.68K ﹤0.01% 1827
2023
Q2
– Sell
-30
Closed -$4K – 2353
2023
Q1
$4K Buy
30
+12
+67% +$1.25K ﹤0.01% 1851
2022
Q4
$2K Hold
18
– – ﹤0.01% 1942
2022
Q3
$2K Buy
18
+5
+38% +$507 ﹤0.01% 1805
2022
Q2
$1K Buy
+13
New +$1.2K ﹤0.01% 1802

Other funds holding NBIX

Blue Trust's NBIX Position: Q3 2026 in Review

Blue Trust increased its Neurocrine Biosciences (NBIX) stake by 13% in Q3 2026, buying an estimated $25.2K and bringing the position to 1,392 shares worth $197K. The position accounts for ﹤0.01% of the portfolio, ranked #769.

Blue Trust first reported a position in NBIX in Q2 2022 and has held it in 17 quarters since. The position peaked at $208K in Q2 2026. 641 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Blue Trust held 1,392 shares of Neurocrine Biosciences worth $197K as of Q3 2026.
  • Blue Trust bought 157 Neurocrine Biosciences shares in Q3 2026, an estimated $25.2K.
  • Neurocrine Biosciences made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #769 holding.
  • Blue Trust first reported a position in Neurocrine Biosciences in Q2 2022 and has held it in 17 quarters since.
  • Blue Trust's Neurocrine Biosciences position peaked at $208K in Q2 2026.
  • 641 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.